Sarepta Therapeutic (SRPT) PT Raised to $81 at Needham & Company
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer
September 20, 2016 1:18 PM EDTOppenheimer analyst Michelle Gilson notes US Patent and Trademark Office ruled in favor of Sarepta (NASDAQ: SRPT) for Patents 7,960,541 and 7,807,816 in its patent interference proceeding (interference number 106,008).
Gilson notes these cover composition of matter for eteplirsen, giving the Sarepta freedom to operate... More
Sarepta Therapeutic (SRPT) PT Raised to $66 at Wedbush
September 20, 2016 7:21 AM EDTWedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $66.00 (from $36.00) after the FDA approved eteplirsen.
Behanna commented, "In line with our expectations after FDA asked for new data, eteplirsen has received accelerated... More
RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A Target
September 19, 2016 1:52 PM EDTRBC Capital upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Sector Perform to Outperform with a price target of $83.00 (from $5.00).
Analyst Simos Simeonidis commented, "In one of the most perplexing regulatory decisions in recent history, FDA has granted accelerated approval to Sarepta's eteplirsen.... More
Leerink Partners Upgrades Sarepta Therapeutic (SRPT) to Market Perform
September 19, 2016 1:29 PM EDTLeerink Partners upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Underperform to Market Perform with a price target of $50.00 (from $5.00).
Analyst Joseph Schwartz commented, "Sarepta's eteplirsen (Exondys 51, Duchenne Muscular Dystrophy) surprisingly received FDA's accelerated approval (AA), in stark contrast to the FDA's negative commentary... More
Sarepta (SRPT) PT Raised to $76 at Oppenheimer Amid Eteplirsen Approval
September 19, 2016 1:08 PM EDTOppenheimer analyst Michelle Gilson reiterated an Outperform rating and raised her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $76.00 (from $60.00) after the FDA announced the approval of eteplirsen (EXONDYS 51) for the treatment of all boys with DMD amenable to Exon 51 skipping.
Gilson... More
Unusual 11 Mid-Day Movers 9/19: (SRPT) (ISLE) (NSAT) Higher; (VICL) (MGT) (MICT) Lower
September 19, 2016 12:56 PM EDTSarepta Therapeutics' (Nasdaq: SRPT) 88.6% HIGHER; The U.S. Food and Drug Administration today approved Sarepta Therapeutics' Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with DMD.
Isle of Capri Casinos, Inc. (Nasdaq: ISLE) 30.2% HIGHER; Eldorado Resorts, Inc. and Isle of Capri Casinos, Inc.... More
Streetinsider.com's Hot Lunchtime Reads 9/19: (PYPL) (WBMD) (SRPT) (FDX)
September 19, 2016 12:22 PM EDTThe following is a list of notable articles to help get you through the lunch hour:WebMD (WBMD) PT Lowered to $63 at Mizuho as New CEO Abruptly Announced ->... More
Sarepta Therapeutic (SRPT) PT Raised to $102 at Baird
September 19, 2016 12:21 PM EDT(Updated - September 19, 2016 12:23 PM EDT)
Baird reiterated an Outperform rating and raised its price target on Sarepta Therapeutic (NASDAQ: SRPT) to $102.00 (from $23.00) following FDA approval of eteplirsen.
Analyst Brian Skorney commented, "After months of delays, requests for additional data, and... More
SunTrust Upgrades Sarepta Therapeutic (SRPT) to Neutral
September 19, 2016 11:43 AM EDTSunTrust Robinson Humphrey upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Reduce to Neutral with a price target of $48.00 (from $4.00).
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $28.15 yesterday.
... MoreSarepta Therapeutics (SRPT) Shorts Squeezed After Eteplirsen Receives FDA Approval
September 19, 2016 11:27 AM EDTSarepta Therapeutics (NASDAQ: SRPT) shorts were pressured after the FDA approved its DMD drug eteplirsen. The news sent shares up over 90% intraday and caught many shorts sellers off guard. According to Nasdaq data from August 31st, short interest was 14.8 million shares, or... More
Sarepta Therapeutics (SRPT) Pushes to Highs Following FDA Approval; +90%
September 19, 2016 11:21 AM EDTSarepta Therapeutics (NASDAQ: SRPT) trading at the highs of the session following FDA approval. Shares are up 90.7%
... MorePiper Jaffray Upgrades Sarepta Therapeutic (SRPT) to Overweight
September 19, 2016 10:58 AM EDTPiper Jaffray upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Overweight with a price target of $64.00 (from $17.00).
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $28.15 yesterday.
... MoreJanney Montgomery Scott Upgrades Sarepta Therapeutic (SRPT) to Buy
September 19, 2016 10:41 AM EDTJanney Montgomery Scott upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Buy with a price target of $65.00.
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $28.15 yesterday.
... MoreSarepta Therapeutic (SRPT) Label More Inclusive Than Anticipated - Oppenheimer
September 19, 2016 10:40 AM EDTOppenheimer analyst Michelle Gilson reiterated an Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA announced the approval of eteplirsen (EXONDYS51) for the treatment of DMD amenable to Exon 51 skipping.
In conjunction with eteplirsen's accelerated approval, Sarepta will... More
William Blair Upgrades Sarepta Therapeutic (SRPT) to Outperform
September 19, 2016 10:35 AM EDTWilliam Blair upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Perform to Outperform with a price target of $88.00.
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $28.15 yesterday.
... MoreSarepta Therapeutics (SRPT) Pares Gains Following FDA Approval
September 19, 2016 10:14 AM EDTSarepta Therapeutics (NASDAQ: SRPT) gives up big chunk of gains following approval. Shares up 53% after trading up over 80%.
... MoreSarepta (SRPT) calls active after FDA approves eteplirsen
September 19, 2016 10:03 AM EDTSarepta Therapeutics (NASDAQ: SRPT) September and October 43 calls are active after a post to the website of the FDA indicated that the regulator granted approval for eteplirsen, the company's treatment of Duchenne muscular dystrophy.
... MoreSarepta Therapeutics (SRPT) Shares Resume Trading; Now Up 82% on FDA Eteplirsen Approval
September 19, 2016 9:59 AM EDTSarepta Therapeutics (NASDAQ: SRPT) is up 82% after re-opening on accelerated approval for eteplirsen
... MoreFDA Approves Sarepta Therapeutics' (SRPT) Eteplirsen
September 19, 2016 9:52 AM EDT(Updated - September 19, 2016 9:56 AM EDT)
The U.S. Food and Drug Administration today approved Sarepta Therapeutics' (Nasdaq: SRPT) Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with DMD.
Patients with a particular type of Duchenne muscular dystrophy will now have access to an approved treatment for this rare and devastating disease, said Janet Woodcock, M.D., director of the... More
Sarepta Therapeutics (SRPT) Granted FDA Accelerated Approval for Eteplirsen
September 19, 2016 9:51 AM EDTSarepta Therapeutics (NASDAQ: SRPT) surges higher on FDA approval for eteplirsen
Letter from FDA
... More